DOI: 10.1055/s-00000134

Diabetologie und Stoffwechsel

References

Home PD, Pocock SJ, Beck-Nielsen H.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Lancet 2009;
373: 2125-2135

Download Bibliographical Data

Access: